The meaning of metabolic syndrome X in patients suffering with benign prostatic hyperplasia

Korean Journal of Urology

Volumn 48, Issue 7, 2007, Pages 696-700

  Park, Jeong Seon ^a   Park, Jong Kwan ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Benign prostatic hyperplasia; Erectile dysfunction; Metabolic syndrome X

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

ARTICLE; BLOOD PRESSURE; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; EDUCATION PROGRAM; ERECTILE DYSFUNCTION; FLOW RATE; FUNCTION TEST; GLUCOSE BLOOD LEVEL; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; MALE; METABOLIC SYNDROME X; MICTURITION DISORDER; OBESITY; ORGAN SIZE; PATIENT ASSESSMENT; PROSTATE HYPERTROPHY; RESIDUAL VOLUME; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TRANSRECTAL ULTRASONOGRAPHY;

EID: 34547542383     PISSN: 04944747     EISSN: None     Source Type: Journal    
DOI: 10.4111/kju.2007.48.7.696     Document Type: Article

References (26)

1. Kim JH, Shim BS, Hong YS. The relating factors of metabolic syndrome to benign prostatic hyperplasia. Korean J Urol 2005; 46:1046-50
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9
3. Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin North Am 1995;22:237-46
4. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 2002;106:599-604
5. Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology 1999;53:1-6
6. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999;8:29-36
7. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
8. Matsuda T, Abe H, Suda K. Relation between benign prostatic hyperplasia and obesity and estrogen. Rinsho Byori 2004; 52:291-4
9. Boon TA, Van Venrooij GE, Eckhardt MD. Effect of diabetes mellitus on lower urinary tract symptom and dysfunction in patients with benign prostatic hyperplasia. Curr Urol Rep 2001;2:297-301
10. Holtgrewe HL. Economic issues and the management of benign prostatic hyperplasia. Urology 1995;46(3 Suppl A):23-5
11. Cohen PG. Aromatase, adiposity, aging and disease. The hypogonadal-metabolic-atherogenic-disease and aging connection. Med Hypotheses 2001;56:702-8
12. Guay AT. Sexual dysfunction in the diabetic patient. Int J Impot Res 2001;13(Suppl 5):S47-50
13. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-9
14. Guirao Sanchez L, Garcia-Giralda Ruiz L, Sandoval Martinez C, Mocciaro Loveccio A. Erectile dysfunction in primary care as possible marker of health status: associated factors and response to sildenafil. Aten Primaria 2002;30:290-6
15. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97
16. Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287: 356-9
17. Christensen MM, Bruskewitz RC. Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention. Urol Clin North Am 1990;17:509-16
18. Nugent AP. The metabolic syndrome. BNF Nutr Bull 2004; 29:36-43
19. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990;17:477-86
20. Michel MC, Mehlburger L, Schumacher H, Bressel HU, Goepel M. Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia. J Urol 2000; 163:1725-9
21. Fonseca V, Seftel A, Denne J, Fredlund P. Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trial. Diabetologia 2004;47:1914-23
22. Landsberg L. Diet, obesity and hypertension: an hypothesis involving insulin, the sympathetic nervous system, and adaptive thermogenesis. Q J Med 1986;61:1081-90
23. Berne C, Pollare T, Fagius J. The sympathetic outflow in vasoconstrictor nerve fascicles to muscle is increased during euglycacemic hyperinsulinemia. Diabetologia 1989;32(Suppl): 465A
24. Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate cancer Prostatic Dis 1998;1:157-62
25. Sugaya K, Kadekawa K, Ikehara A, Nakayama T, Gakiya M, Nashiro F, et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia. Int J Urol 2003;10:569-74
26. Kim JH, Shim BS, Kim JS, Hong YS. Voiding dysfunction of men is associated metabolic syndrome. Korean J Urol 2006;47:257-62